iTeos Therapeutics (ITOS)
(Real Time Quote from BATS)
$10.11 USD
0.00 (0.00%)
Updated Aug 6, 2025 02:16 PM ET
4-Sell of 5 4
D Value C Growth C Momentum D VGM
Fundamental Charts
About Market Cap
As of the previous market close, iTeos Therapeutics, Inc. has a market cap of $386.95M, which represents its share price of $10.11 multiplied by its outstanding shares number of 38.27M. As a small-cap company, ITOS's shareholders are generally exposed to more risk than shareholders of mid and large-cap companies.
The company's Market Capitalization is a measurement of company size. It is calculation of the company's share price times the number of outstanding shares. Large market cap companies give stability and are good long-term investments. Small market cap companies can produce faster growth and bigger returns, but their stockholders are exposed to more risk.
ITOS 10.11 0.00(0.00%)
Will ITOS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ITOS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ITOS
iTeos Therapeutics (ITOS) Upgraded to Buy: Here's What You Should Know
GSK Inks $2B Deal With Boston Pharmaceuticals to Buy Liver Disease Drug
ITOS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts See a 211.07% Upside in iTeos Therapeutics (ITOS): Can the Stock Really Move This High?
Wall Street Analysts Think iTeos Therapeutics (ITOS) Could Surge 212.5%: Read This Before Placing a Bet
All You Need to Know About iTeos Therapeutics (ITOS) Rating Upgrade to Buy
Other News for ITOS
Ridgeback Capital Investments L.P. Acquires Significant Stake in ITeos Therapeutics Inc.
iTeos Therapeutics (ITOS) Downgraded Following Merger Agreement | ITOS Stock News
iTeos Therapeutics just downgraded at Piper Sandler, here's why
iTeos Therapeutics (ITOS) Agrees to Acquisition by Concentra Biosciences
Vor Bio appoints Cumbo, Detheux to board of directors